AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.
The company said it has been granted approval to import and market trastuzumab deruxtecan used in the treatment of select "HER-2 positive" breast cancer.
"The India approval is based on a global, head-to-head, randomised, open label, registrational Phase III trial DESTINY Breast 03. Globally, trastuzumab deruxtecan is approved in more than 40 countries, including the US, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer," AstraZeneca Pharma India said in a statement.
HER2 is a form of growth-promoting protein expressed on the surface of multiple tumours, including breast, gastric, lung and colorectal cancers, and is one of the biomarkers expressed in breast cancer tumours, it added.
"India's approval of trastuzumab deruxtecan marks a significant clinical advancement allowing us to help more patients across the HER2 spectrum," AstraZeneca India Country President and Managing Director Sanjeev Panchal said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
After Pharma Firm's Huge Eye Drop Claim, Regulator Withdraws Permission Only Processing Charges To Be Levied For Procuring Blood At Hospitals, Blood Banks: Drug Regulator Sale Of False Version Of 2 Drugs To Be Monitored In India After WHO Alert Amazon Employee Greets Friend At Wedding, Dies Of Cardiac Arrest "Violation Of Sovereignty, Abuse Of Power": Kanwal Sibal On US Report On Adani Group Indian Student In US Accidentally Shoots Himself Dead While Celebrating Birthday Sweden Says Won't Be Intimidated By Putin's Warning To West Karishma Tanna Shares Her Secret Hacks To Prevent Hair Fall 'Odisha Had No Dealings With Adani Group': BJD Rejects US Charge Track Latest News Live on NDTV.com and get news updates from India and around the world.